In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals in Depth: December 2009

Executive Summary

Astellas will be developing Ambit's FLT3 kinase blockers in the month's largest deal at $390 million. Sanofi-Aventis' move into the US OTC market was evident in its acquisition of Chattem for $2.1 billion. In one of the five biggest medical device acquisitions of 2009, Ethicon bought sinus surgical device company Acclarent for $785 million. Financing for biopharma companies increased dramatically to over $2 billion, most of which came from three $400 million-plus FOPOs. Device fundraising was down slightly in December, although diabetes management firm Intuity Medical impressed with its $64 million Series D round.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts